Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million

The new company, co-founded by ex-Lilly executive Steven Paul, plans to move aggressively with its allosteric modulators, launching the first of several clinical programs within six months to a year.